To identify the association between ACSL1 and the drug response of the PARP1 inhibitor talazoparib, we perform an analysis of variance (ANOVA) using data from the Genomics of Drug Sensitivity Cancer (GDSC) database to correlate drug response [inhibitory concentration (IC50) values of talazoparib] with genetic alterations (mutations and CNA) in cancer cells. Here, PARP1 is linked to cancer.